PROMUS™ Everolimus-Eluting Coronary Stent System

Product Information

Optimal Olimus DES ^1-7
Multi-Link Vision™ Stent Platform¹
Exceptional deliverability

• Thin struts (.0032") (0.081mm)
• Low system profile (.042") (1.067mm)

Optimal Drug & Polymer Design^2-4

• Low drug load compared to other Olimus stents
• Everolimus is highly lipophilic ^5-7
• Thin, durable polymer matrix results in controlled release of Everolimus

Early Clinical Experience⁸
SPIRIT Trial Program

• SPIRIT First 3.8% (6 month)
• SPIRIT II 1.8% (6 month)
• SPIRIT III 2.6% (9 month)

• SPIRIT First 0.10mm (6 month)
• SPIRIT II 0.11mm (6 month)
• SPIRIT III 0.16mm (8 month)

Product Illustration

Additional Information

1. Testing completed by Boston Scientific Corporation, N=6. Data on file. Bench test results may not necessarily be indicative of clinical performance. Testing includes Cypher™ Stent, Cypher Select™ Stent & Endeavor™ Stent. Cypher and Cypher Select are trademarks of Cordis Corp. Endeavor is a trademark of Medtronic Vascular, Inc. Vision is a trademark of Abbott Laboratories group of companies.
2. PROMUS™ Stent, Instructions for Use (IFU).
3. Cypher™ Instructions for Use (IFU).
4. D. Kandzari & M. Leon: Overview of Pharmacology and Clinical Trials Program with the Zotarolimus-Eluting Endeavor™ Stent, J Interven Cardiol (2006) 19: 405–413.
5. Circulation, 2004;109:2168-2171.
6. The American Society for Pharmacology and Experimental Therapeutics, 1999;27:627-632.
7. Pharmaceutical Research. 1998;15:1666-1672.
8. SPIRIT is sponsored by Abbott. SPIRIT First: Serruys, et al., Eurointervention 2005, 1:58-65 and 12-month data - Tsuchida, et al., Eurointervention 2005, 1:266-272. SPIRIT II Clinical Trial Results Presentation ESC 2006; Presented by Dr. Patrick Serruys.
   PROMUS is a trademark of Boston Scientific Corporation or its affiliates. PROMUS™ stent is a private-labeled XIENCE™ V Everolimus Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific Corporation.